Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

90Y Ibritumomab Tiuxetan

90Y Ibritumomab Tiuxetan Am J Cancer 2002; 1 (5): 349 GUEST COMMENTARIES 1175-6357/02/0005-0349/$25.00/0 © Adis International Limited. All rights reserved. • with many effective choices available for patients with follic- Y Ibritumomab Tiuxetan A Viewpoint by Ted Wun ular lymphoma, what is the best sequence of therapies? Underly- ing these decisions is the concept that therapy is palliative rather Division of Hematology Oncology, UCDMC, Sacremento, USA than curative; no regimen has yet to result in prolonged survival. Patient preference, experience of the treating oncologist, conve- Lymphomas are a diverse group of lymphoid malignancies nience, and cost are considerations with varying clinical and pathologic characteristics. Many pa- • to date, most RIT has been delivered in specialized centers to tients have follicular lymphoma, which are typically clinically selected patients. Patients with significant bone marrow compro- indolent, widespread at diagnosis, and usually incurable. Treat- mise or substantial involvement by lymphoma, abnormal radio- ment has traditionally been alkylating agent-based chemotherapy pharmaceutical biodistribution on imaging, progressive disease and/or external beam radiation. Purine analog-based regimens have after stem cell transplantation, and those with significant num- also proven their utility. The human-mouse chimeric monoclonal bers of circulating malignant cells have not been treated antibody rituximab, which targets the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

90Y Ibritumomab Tiuxetan

American Journal of Cancer , Volume 1 (5) – Aug 10, 2012

90Y Ibritumomab Tiuxetan

Abstract

Am J Cancer 2002; 1 (5): 349 GUEST COMMENTARIES 1175-6357/02/0005-0349/$25.00/0 © Adis International Limited. All rights reserved. • with many effective choices available for patients with follic- Y Ibritumomab Tiuxetan A Viewpoint by Ted Wun ular lymphoma, what is the best sequence of therapies? Underly- ing these decisions is the concept that therapy is palliative rather Division of Hematology Oncology, UCDMC, Sacremento, USA than curative; no regimen has yet to result in...
Loading next page...
 
/lp/springer-journals/90y-ibritumomab-tiuxetan-Lq5W5GIe4s
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201050-00005
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2002; 1 (5): 349 GUEST COMMENTARIES 1175-6357/02/0005-0349/$25.00/0 © Adis International Limited. All rights reserved. • with many effective choices available for patients with follic- Y Ibritumomab Tiuxetan A Viewpoint by Ted Wun ular lymphoma, what is the best sequence of therapies? Underly- ing these decisions is the concept that therapy is palliative rather Division of Hematology Oncology, UCDMC, Sacremento, USA than curative; no regimen has yet to result in prolonged survival. Patient preference, experience of the treating oncologist, conve- Lymphomas are a diverse group of lymphoid malignancies nience, and cost are considerations with varying clinical and pathologic characteristics. Many pa- • to date, most RIT has been delivered in specialized centers to tients have follicular lymphoma, which are typically clinically selected patients. Patients with significant bone marrow compro- indolent, widespread at diagnosis, and usually incurable. Treat- mise or substantial involvement by lymphoma, abnormal radio- ment has traditionally been alkylating agent-based chemotherapy pharmaceutical biodistribution on imaging, progressive disease and/or external beam radiation. Purine analog-based regimens have after stem cell transplantation, and those with significant num- also proven their utility. The human-mouse chimeric monoclonal bers of circulating malignant cells have not been treated antibody rituximab, which targets the

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.